Cytokinetics (CYTK) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Cytokinetics (NASDAQ: CYTK) in the last few weeks:

• 8/16/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/14/2026 – Cytokinetics had its “buy” rating reaffirmed by HC Wainwright.
• 8/13/2026 – Cytokinetics had its price target raised by Barclays PLC from $95.00 to $110.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Cytokinetics had its price target raised by JPMorgan Chase & Co. from $97.00 to $103.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Cytokinetics had its price target raised by Truist Financial Corporation from $106.00 to $112.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Cytokinetics had its price target lowered by Royal Bank Of Canada from $117.00 to $112.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – Cytokinetics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/7/2026 – Cytokinetics had its price target raised by Citizens Jmp from $105.00 to $110.00. They now have a “market outperform” rating on the stock.
• 8/7/2026 – Cytokinetics had its price target raised by Needham & Company LLC from $102.00 to $112.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Cytokinetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – Cytokinetics had its price target lowered by Royal Bank Of Canada from $119.00 to $117.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Cytokinetics was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $115.00 price target on the stock, up from $69.00.

Insiders Place Their Bets

In other news, CEO Robert I. Blum sold 7,500 shares of Cytokinetics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total transaction of $636,900.00. Following the sale, the chief executive officer directly owned 377,830 shares in the company, valued at $32,085,323.60. The trade was a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B Lynne Parshall sold 5,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $74.08, for a total transaction of $370,400.00. Following the completion of the transaction, the director directly owned 15,784 shares in the company, valued at $1,169,278.72. This trade represents a 24.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 118,679 shares of company stock valued at $9,382,724. Insiders own 2.60% of the company’s stock.

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.